1,205,587 Shares in USANA Health Sciences, Inc. $USNA Bought by Pzena Investment Management LLC

Key Points

• Pzena Investment Management acquired 1.21 million USANA shares worth approximately $25.7 million, giving it a 6.53% stake. Institutional investors collectively own 54.25% of the company.
• USANA shares opened at $12.79, near their 12-month low of $12.58, after the company reported a quarterly loss of $0.07 per share and revenue of $223.27 million, both below analyst expectations.
• Analyst sentiment remains negative: Weiss Ratings maintained a sell rating, while Wall Street Zen and Zacks downgraded the stock; MarketBeat reports a consensus rating of Sell. Insiders have also sold $261,441 of shares over the past 90 days.

Pzena Investment Management LLC bought a new stake in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,205,587 shares of the company's stock, valued at approximately $25,739,000. Pzena Investment Management LLC owned approximately 6.53% of USANA Health Sciences as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of USANA Health Sciences during the 2nd quarter valued at about $33,182,000. Renaissance Technologies LLC increased its holdings in shares of USANA Health Sciences by 1.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company's stock worth $22,522,000 after purchasing an additional 21,793 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of USANA Health Sciences by 5.7% in the third quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company's stock worth $29,452,000 after purchasing an additional 57,249 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of USANA Health Sciences by 1.9% in the third quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company's stock worth $25,210,000 after purchasing an additional 17,318 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in shares of USANA Health Sciences in the fourth quarter worth about $11,485,000. 54.25% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director John Turman Fleming sold 2,450 shares of the firm's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the sale, the director directly owned 4,230 shares in the company, valued at $75,843.90. This trade represents a 36.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brent Neidig sold 5,002 shares of the firm's stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total value of $97,288.90. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 13,869 shares of company stock valued at $261,441. 0.82% of the stock is currently owned by insiders.

Analyst Ratings Changes

USNA has been the subject of a number of research reports. Weiss Ratings reissued a "sell (d)" rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Wall Street Zen downgraded USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Zacks Research downgraded USANA Health Sciences from a "hold" rating to a "strong sell" rating in a research report on Thursday, August 6th. Two investment analysts have rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of "Sell".

USANA Health Sciences Trading Down 4.3%

Shares of NYSE:USNA opened at $12.79 on Tuesday. The company has a market cap of $236.14 million, a price-to-earnings ratio of -10.57, a PEG ratio of 1.47 and a beta of 0.73. USANA Health Sciences, Inc. has a 12 month low of $12.58 and a 12 month high of $32.32. The company has a 50-day moving average price of $19.86 and a 200 day moving average price of $19.28.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.50). The company had revenue of $223.27 million for the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. As a group, equities analysts forecast that USANA Health Sciences, Inc. will post 0.76 EPS for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source